Mangoceuticals, Inc. Common Stock (MGRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mangoceuticals, Inc. Common Stock (MGRX) has a cash flow conversion efficiency ratio of -0.079x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.24 Million) by net assets ($15.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MGRX equity financing ratio to measure how much of total assets are equity-financed.
Mangoceuticals, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Mangoceuticals, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Mangoceuticals, Inc. Common Stock cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Mangoceuticals, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mangoceuticals, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Can Fite Biopharma Ltd
TA:CANF
|
-0.425x |
|
MEKICS Co Ltd
KQ:058110
|
-0.012x |
|
JW Pharmaceutical Corp
KO:001067
|
0.132x |
|
Indal Aluminium Industry Tbk
JK:INAI
|
0.399x |
|
Safello Group AB
ST:SFL
|
-0.015x |
|
SC Estate Builder Bhd
KLSE:0109
|
-0.098x |
|
PLAYWITH Inc
KQ:023770
|
-0.027x |
|
New Age Exploration Ltd
AU:NAE
|
-0.044x |
Annual Cash Flow Conversion Efficiency for Mangoceuticals, Inc. Common Stock (2021–2024)
The table below shows the annual cash flow conversion efficiency of Mangoceuticals, Inc. Common Stock from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see Mangoceuticals, Inc. Common Stock market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.95 Million | $-4.86 Million | -0.349x | +96.14% |
| 2023-12-31 | $774.75K | $-7.00 Million | -9.032x | -311.86% |
| 2022-12-31 | $614.03K | $-1.35 Million | -2.193x | -309.28% |
| 2021-12-31 | $-16.72K | $-17.52K | 1.048x | -- |
About Mangoceuticals, Inc. Common Stock
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also p… Read more